# Cannabinoid Clinical Trials: Cannabis Dosing for Insomnia > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-clinical-trials-insomnia/ > **Published:** 2026-03-13T13:18:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:07:58-04:00 > **Clinical Summary:** Explore cannabinoid clinical trials insomnia research focusing on cannabis dosing effects and sleep architecture in insomnia patients. --- #### Clinical Takeaway In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo. These findings suggest that, at least acutely, this cannabinoid combination did not improve objective sleep in this population, and next-day alertness effects were also measured using high-density EEG. Clinicians should be cautious about recommending oral cannabinoids for insomnia based on perceived benefit alone, as objective sleep architecture data may not support subjective impressions of improved sleep. ### #9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. **Citation:** Suraev Anastasia et al. *Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.* Journal of sleep research. 2026. PMID: 40631525. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 11 Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 Why This Matters This pilot study provides the first high-density EEG characterization of how a standardized THC/CBD combination affects sleep architecture and cortical activity in patients with clinically diagnosed insomnia disorder, addressing a critical gap between cannabis’s widespread use as a sleep aid and limited objective neurophysiological evidence. The detailed EEG data on sleep stage progression and next-day alertness will help clinicians distinguish between subjective sleep improvements and actual changes in sleep physiology, informing more evidence-based prescribing decisions for insomnia patients considering [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/). **Methodological Considerations:** - Self-reported outcomes — recall and social-desirability bias risk **Abstract:** Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/. Clinical Perspective This pilot study offers useful objective data on [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) on sleep architecture in insomnia patients, showing that a single dose of THC/CBD altered EEG patterns in ways consistent with sedation, yet the small sample size (n=20), single-dose design, and lack of longer-term follow-up limit our ability to draw conclusions about sustained efficacy or tolerance development. The unusually high CBD-to-THC ratio (20:1) and predominance of female participants may not generalize to typical cannabis users or diverse patient populations, and we cannot yet determine whether observed EEG changes translate to clinically meaningful improvements in daytime function or [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). Additionally, the study does not address potential next-night rebound insomnia or interactions with other sedating medications commonly used in this population. For practitioners considering cannabinoids in insomnia, this work supports the value of objective sleep monitoring but suggests we should counsel patients that a single positive EEG finding does not establish long-term safety or superiority over  |   |  Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://cedclinic.com/dea-temporary-placement-schedule-i-n-desethyl-isotonitazene/) Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40631525/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12856102/)[DOI ↗](https://doi.org/10.1111/jsr.70124) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Oral Cannabinoids Improve Sleep Quality in Insomnia Patients: Evidence from a Randomized Controlled Trial](https://cedclinic.com/oral-thc-cbd-insomnia-trial-sleep-quality-effects/) This study provides evidence on how oral cannabinoids can improve sleep quality in patients with insomnia through a randomized controlled trial. [Read More](https://cedclinic.com/oral-thc-cbd-insomnia-trial-sleep-quality-effects/) [Cannabinoid Sleep Trials: EEG Insomnia Research (2026)](https://cedclinic.com/cannabinoid-sleep-trials-insomnia-eeg-research-2026/) Explore EEG-based insomnia research from 2026 focusing on cannabinoid sleep trials and their neurophysiological effects. [Explore Study](https://cedclinic.com/cannabinoid-sleep-trials-insomnia-eeg-research-2026/) [Cannabinoid Clinical Trials: Sleep & EEG Insomnia Study](https://cedclinic.com/cannabinoid-clinical-trials-sleep-eeg-insomnia-study/) Detailed [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) examining cannabinoid effects on sleep and EEG patterns in insomnia patients. [Learn More](https://cedclinic.com/cannabinoid-clinical-trials-sleep-eeg-insomnia-study/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis%20Dosing%20for%20Insomnia&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-insomnia-cannabis-dosing%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-insomnia-cannabis-dosing%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis%20Dosing%20for%20Insomnia%20https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-insomnia-cannabis-dosing%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).